TLPPF (TLPPF) Stock Price & Analysis
TLPPF (TLPPF) rose 0.67% to USD 10.48 as of July 26, 2026 at 08:19 UTC, according to Nexqual real-time market data.
TLPPF last closed at USD 10.41; the session ranged USD 10.41–10.41 on volume of 100 shares. Market capitalization is $3.55B, with a 52-week range of USD 5.91–13.75 (PNK). Source: Nexqual, July 26, 2026 at 08:19 UTC.
Key Statistics (as of July 26, 2026 at 08:19 UTC)
| Price | USD 10.48 |
|---|---|
| Change | ▲ 0.67% (up) |
| Previous Close | USD 10.41 |
| Open | USD 10.41 |
| Day Range | USD 10.41 – 10.41 |
| 52-Week Range | USD 5.91 – 13.75 |
| Volume | 100 shares |
| Market Cap | $3.55B |
| Exchange | PNK |
Technical Analysis (TLPPF)
Nexqual's technical model rates TLPPF "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 26, 2026 at 08:19 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.54 (neutral) |
| vs SMA50 | Above (USD 10.16) |
| MACD | 0.05 (positive) |
Analyst Ratings (TLPPF)
Wall Street analysts rate TLPPF "None", per Nexqual as of July 26, 2026 at 08:19 UTC.
| Consensus Rating | None |
|---|
Earnings (TLPPF)
| Revenue Estimate | $311.55M |
|---|
Source: Nexqual, July 26, 2026 at 08:19 UTC.
Financials & Fundamentals (TLPPF)
| Total Revenue | $803.79M |
|---|---|
| Revenue Growth (YoY) | +49.30% |
| Gross Margin | +47.50% |
| Operating Margin | +1.94% |
| Profit Margin | -0.89% |
| ROE | -1.86% |
| Debt / Equity | 112.45 |
| Current Ratio | 1.43 |
| Total Cash | $141.87M |
| Total Debt | $467.11M |
| Free Cash Flow | $-36.67M |
Source: Nexqual, July 26, 2026 at 08:19 UTC.
Financial Health Score (TLPPF)
Nexqual rates TLPPF's overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 08:19 UTC.
| Growth | Strong — Revenue +53% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 48%, operating 2% |
| Balance Sheet | Mixed — $142M cash vs $467M debt |
| Cash Flow | Weak — FCF negative: -$37M, burning cash |
| Efficiency | Critical — ROE -2%, ROA 1.1% |
Ownership (TLPPF)
| Insider Ownership | +16.90% |
|---|---|
| Institutional Ownership | +32.88% |
| Shares Outstanding | 338.78M |
| Float | 272.81M |
Source: Nexqual, July 26, 2026 at 08:19 UTC.
Leadership (TLPPF)
TLPPF is led by Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D. (age 49), Co-Founder, MD, Group CEO & Executive Director, per Nexqual as of July 26, 2026 at 08:19 UTC.
| Co-Founder, MD, Group CEO & Executive Director | Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D. (age 49) |
|---|---|
| Group Chief Financial Officer | Darren Smith B.Bus., FCPA (age 60) |
| Group Chief Operating Officer | Darren Patti Pharm.D. (age 52) |
| Senior Vice President of Corporate Communications & Investor Relations | Kyahn Williamson B.A. |
| Vice President of Sales | Thomas Fromm |
Major Backers & Investors (TLPPF)
Notable institutional backers of TLPPF include DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series, Charles Schwab, according to Nexqual as of July 26, 2026 at 08:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series | 0.27% |
| Charles Schwab | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.05% |
| State Street | 0.2% |
| BlackRock | 0.15% |
Source: Nexqual, July 26, 2026 at 08:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IVBXF | Innovent Biologics Inc. | USD 10.83 | ▼ 15.39% |
| ZLDPF | Zealand Pharma A/S | USD 45.02 | ▲ 0.97% |
| UCBJY | UCB S.A. | USD 139.01 | ▼ 0.04% |
| WXIBF | Wuxi Biologics (Cayman) Inc | USD 4.6 | ▲ 0% |
| PTCHF | PureTech Health PLC | USD 1.6 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 08:19 UTC. This page is informational and not investment advice.